Search company, investor...
Imagia Canexia Health company logo

Imagia Canexia Health

Founded Year



Biz Plan Competition | Alive

Total Raised


About Imagia Canexia Health

Imagia Canexia Health enables collaborative AI by providing outcome-based structured clinical data and federated learning capabilities across multiple sources and researchers. Imagia's Evidens Platform uses routine clinical patient data, designed to deliver care, into outcome-based structured information appropriate for AI biomarker discovery. Imagia Healthcare delivers AI clinical solutions to B2B partners, as R&D tools, digital health products, or fully regulated software-as-medical-devices validated through the ISO13485 MDSAP certified quality system.

Headquarters Location

6650 Saint-Urbain Suite 100

Montreal, Quebec, H2S 3G9,



Imagia Canexia Health's Product Videos

Compete with Imagia Canexia Health?

Ensure that your company and products are accurately represented on our platform.

Imagia Canexia Health's Products & Differentiators

    Find It (Tissue)

    Tissue based test for treatment selection

Expert Collections containing Imagia Canexia Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Imagia Canexia Health is included in 4 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

10,627 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health

10,338 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Health IT

7,901 items

Imagia Canexia Health Patents

Imagia Canexia Health has filed 5 patents.

The 3 most popular patent topics include:

  • Geometrical optics
  • Optical devices
  • Association football record progressions
patents chart

Application Date

Grant Date


Related Topics




Machine learning, Artificial neural networks, Medical imaging, Classification algorithms, Image processing


Application Date


Grant Date



Related Topics

Machine learning, Artificial neural networks, Medical imaging, Classification algorithms, Image processing



Latest Imagia Canexia Health News

AR and VR lens technology company Imagia raises $4.5M in seed funding

May 2, 2023

May 2, 2023 – Imagia , a developer of next-generation lens technology, has recently announced the close of a USD $4.5M seed round. Led by Gates Frontier and joined by MetaVC Partners and other strategic investors, the funding will help Imagia to accelerate the development and initial commercial deployment of the company’s first generation of flat, silicon-based optical lenses. Imagia stated that its metalens technology can shrink an entire optical assembly into a planar, wafer-thin device, resulting in a dramatic reduction in size and complexity for optical assemblies. According to Imagia, using a patent-pending approach, the company’s technology can precisely pattern nanoscale structures directly onto various substrates, creating completely flat metalenses that steer light waves by design, and without the need for traditional curved lenses. The lenses can be square or round, and can be made as small as a single pixel on a digital display. Imagia noted that makers of complex optoelectronic products such as augmented and virtual reality (AR/VR) headsets are constantly having to make tradeoffs between ergonomic form and optical function due to constraints and limitations of traditional bulk optics. These limitations no longer apply with metalenses, which afford manufacturers more optical design flexibility to achieve higher-performing products with a reduction in size, weight and complexity, according to Imagia. The company also claims that its approach allows for completely new device architectures; its metalenses can be built directly on top of CMOS* devices like LEDs and image sensors in the same fabrication flow, which eliminates several critical steps of opto-mechanical alignment. *Complementary metal-oxide semiconductors are the semiconductor technology used in most of today’s microchips. A single Imagia metalens can replace an entire stack of traditional bulk optics, according to the company. “Metamaterials are a true paradigm shift in the way we manipulate light, akin to the shift from analog to digital computing,” said Greg Kress, CEO of Imagia. “Traditional glass lenses have been around for hundreds of years. The inherent constraints of working with these types of lenses result in complex, bulky optical assemblies that require precise mechanical alignments. Imagia changes that approach by building lenses like integrated circuits, something that was not possible until very recently.” Currently at the prototype stage, Imagia stated that its metalens technology has demonstrated an overall reduction in optical system volume by >90% in a variety of applications including lightweight, high-performance AR glasses and next-generation holographic displays. The company added that it is also working to lay the foundation to expand into image sensing lens design, in order to bring significant benefits to smartphone camera, satellite and computer vision system design, according to Imagia. “We are firm believers that the next generation of AR glasses will be powered by this kind of metalens technology,” said David Bonelli, Founder & CEO of Pulsar , the AR hardware and optics design firm behind Red6’s ATARS and NuEyes’s NuLoupes . “Imagia’s metalens technology promises to open up new frontiers in optical design that were previously impossible.” Imagia added that it is now working in partnership with Pulsar to explore future applications for metalenses. Founded by Greg Kress, a Stanford PhD engineer, and led by a team of optical physicists and materials science engineers, Imagia is aiming to reshape the next generation of high-performance optoelectronics devices through its patent-pending metalens technology, and the use of proprietary, silicon-based optical materials and state-of-the-art lithography tools. Imagia noted that it is currently developing products for customers in augmented reality displays and LED illumination. For more information on Imagia and its next-generation lens technology for the XR industry, please visit the company’s website . Image credit: Imagia

Imagia Canexia Health Frequently Asked Questions (FAQ)

  • When was Imagia Canexia Health founded?

    Imagia Canexia Health was founded in 2015.

  • Where is Imagia Canexia Health's headquarters?

    Imagia Canexia Health's headquarters is located at 6650 Saint-Urbain, Montreal.

  • What is Imagia Canexia Health's latest funding round?

    Imagia Canexia Health's latest funding round is Biz Plan Competition.

  • How much did Imagia Canexia Health raise?

    Imagia Canexia Health raised a total of $3.08M.

  • Who are the investors of Imagia Canexia Health?

    Investors of Imagia Canexia Health include Onco-Tech Competition, Canada Economic Development, Investissement Quebec, BDC Healthcare Venture Fund, Fidelity Investments Canada and 6 more.

  • Who are Imagia Canexia Health's competitors?

    Competitors of Imagia Canexia Health include Tempus and 5 more.

  • What products does Imagia Canexia Health offer?

    Imagia Canexia Health's products include Find It (Tissue) and 2 more.

  • Who are Imagia Canexia Health's customers?

    Customers of Imagia Canexia Health include Canadian Digital Technology Supercluster invested in this consortium initiative led by Canexia Health.

Compare Imagia Canexia Health to Competitors

Evidation Logo

Evidation operates as a multichannel health tracking platform. It enables users to connect with multiple appications to track everyday activity and earn rewards for steps, sleep, surveys, and more. The company was founded in 2012 and is based in San Mateo, California.

nference Logo

nference makes biomedical knowledge computable to solve urgent healthcare problems of biopharmas and medical centers. The company offers EMR data, software products and services, record de-identification, curation of unstructured information, and data creation via digitization of pathology and molecular sequencing. It was founded in 2013 and is based in Cambridge, Massachusetts.

Holmusk Logo

Holmusk builds an evidence platform with behavioral health combining behavioral health databases with artificial intelligence (AI) powered analytics and digital solutions. Its technology powers data-driven medicine that uses analytic and digital tools to address the need in healthcare and pharma-life science. The company was founded in 2015 and is based in Singapore, Singapore.

Owkin Logo

Owkin specializes in artificial intelligence technologies applied to clinical research and developing drugs and treatments for patients. It empowers researchers in hospitals, universities, and the biopharma industry to understand drug efficacy varies, improves the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company was founded in 2016 and is based in New York, New York.

Strata Oncology Logo
Strata Oncology

Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials.

Syapse Logo

Syapse develops software for aggregating and structuring biomedical data. It combines data intelligence, insight analytics and applied experience through healthcare organizations looking to transform patients’ lives using real-world evidence. The company was founded in 2008 and is based in San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.